Radiopharm Theranostics
RADX | NASDAQ
$0.72
-$0.04 (-5.26%)
At close: Nov 16, 2026, 3:59 PM ET
$0.70
-$0.02 (-2.78%)
After-hours:
Nov 16, 2026, 7:58 PM ET
Radiopharm Theranostics Company Profile
Company profile explainedCompany Profile
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Key Executives
| Name | Position |
|---|---|
| Riccardo Canevari | MD, Chief Executive Officer & Director |
| Aaron Laurita | Chief Financial Officer |
| Amritha Sushil | Joint Company Secretary |
| Dimitris Voliotis | Chief Medical Officer |
| Hitesh Goel | Head of Project Management |
| Nathan Jong | Joint Company Secretary |
| Paul Edward-Alexander Hopper FAICD | Founder & Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | 6-K | Filing |
| Oct 27, 2026 | 4 | Filing |
| Oct 27, 2026 | 6-K | Filing |
| Oct 26, 2026 | 6-K | Filing |
| Oct 20, 2026 | 6-K | Filing |
| Oct 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 05, 2026 | 6-K | Filing |
| Oct 01, 2026 | 6-K | Filing |
| Sep 30, 2026 | 20-F | Filing |
| Sep 30, 2026 | 6-K | Filing |
Radiopharm Theranostics
| Country | Australia |
| IPO Date | Dec 5, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Riccardo Canevari |
Contact Details
62 Lygon Street Carlton,
VIC 3053 Australia
Stock Details
| Ticker Symbol | RADX |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001949257 |
| CUSIP Number | 75041J101 |
| ISIN Number | US75041J1016 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove RADX